AtriCure, Inc. vs Merck & Company, Inc. — Stock Comparison
AtriCure, Inc. (ATRC) and Merck & Company, Inc. (MRK) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Merck & Company, Inc. narrowly edges AtriCure, Inc. on Q·Score (7 vs 6.8 out of 10), led by Quality (7.7 vs 3.8) and Valuation (6.7 vs 6.3). AtriCure, Inc. scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for ATRC (+63.2%) than for MRK (+13.9%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Clean balance sheet with low leverage (0.2× debt-to-equity).
⚠ currently unprofitable (-1% margin).
High-quality business with 19% return on equity and 14% profit margins.
Analyst Consensus
Fundamentals
Frequently Asked Questions
ATRC vs MRK: which stock scores better overall?
Based on Q·Score, Merck & Company, Inc. (MRK) scores 7/10 versus AtriCure, Inc. (ATRC) at 6.8/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: ATRC or MRK?
AtriCure, Inc. (ATRC) scores higher on Growth (7.5/10 vs 6.2/10). AtriCure, Inc. reports revenue growth (14.3% YoY) while Merck & Company, Inc. reports (4.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is ATRC or MRK more attractively valued?
Merck & Company, Inc. (MRK) scores higher on Valuation (6.7/10 vs 6.3/10). ATRC trades at 82.6× P/E versus MRK at 11.9×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about ATRC vs MRK?
There are 8 analysts covering ATRC with a consensus price target of $47.00, and 27 analysts covering MRK with a consensus target of $129.74. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: ATRC or MRK?
Merck & Company, Inc. (MRK) scores higher on Quality (7.7/10 vs 3.8/10). Net profit margin: ATRC at -0.8%, MRK at 13.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: ATRC or MRK?
AtriCure, Inc. (ATRC) scores higher on Financial Health (9.7/10 vs 7/10). Market beta: ATRC at 1.26, MRK at 0.22. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of ATRC and MRK?
AtriCure, Inc. (ATRC) has a market capitalisation of $1.5B, while Merck & Company, Inc. (MRK) has a market cap of $281.2B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do ATRC or MRK pay dividends?
ATRC does not currently pay a dividend, while MRK pays a dividend yield of 2.95%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →